Profound Medical Corp.

TSX:PRN.TO

Medical - Devices

Healthcare
$9.83 +1.18%

+$0.11 today

Market cap
$360.04M
Beta
0.52
P/E (TTM)
-6.3
EPS (TTM)
-$1.07
52W Low $5.23High $12.40

Volume 0.00M

Average 0.01M

PRN.TO Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Profound Medical Corp.TSX: PRN.TO

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin widens to 71.8%

Gross margin was 71.8% in Q1 FY2026, up 1.1 pp from a year earlier. On a trailing-twelve-month basis it was 71.0%, up 4.1 pp year over year. Over 3 fiscal years it widened by 25.6 pp.

Context

  • Gross margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
71.8%+5.0 pp QoQ
Last fiscal yearDec 2025
70.8%+4.9 pp YoY
LTMMar 2026
71.0%+4.1 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+1.1 pp——
1 year+4.9 pp——
3 years+25.6 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
70.8%
Year-over-year change
+4.9pp

Gross Margin vs competitors

How PRN.TO compares with its peers on the latest reported figures

  • PRN.TO's LTM Mar 2026 gross margin of 71.0% is the highest of the 5 companies compared; the peer median is 46.0%.
  • Its year-over-year change of +4.1 pp is the highest of 5, against a peer median of -13.5 pp.
  • Over three fiscal years its change of +25.6 pp compares with a peer median of -16.0 pp.
PRN.TO Competitors Peer median
Gross Margin for PRN.TO and competitors
Company Period LTM level YoY 3-year change
PRN.TOProfound Medical Corp.LTM Mar 202671.0% +4.1 pp+25.6 pp
HLS.TOHLS Therapeutics Inc.LTM Mar 202661.7% -21.3 pp-49.4 pp
XLY.TOAuxly Cannabis Group Inc.LTM Mar 202647.5% -5.8 pp+39.8 pp
DR.TOMedical Facilities CorporationLTM Mar 202644.5% -21.3 pp-28.1 pp
CRRX.TOCareRx CorporationLTM Mar 202626.5% -3.1 pp-3.8 pp
EPRX.TOEupraxia Pharmaceuticals Inc.FY2025— ——
Peer median (excluding PRN.TO) 46.0%-13.5 pp-16.0 pp

Competitors are the stored peer set for PRN.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue6.87M6.68M7.2M10.68M16.38M
Cost of Revenue3.92M3.66M2.82M3.64M4.79M
Gross Profit2.95M3.02M4.38M7.04M11.59M
Gross Margin43.0%45.2%60.9%65.9%70.8%
Research & Development15.28M14.69M14.38M16.97M20.96M
Selling, General & Admin17.97M17.93M18.62M23.13M32.61M
Operating Expenses33.24M32.62M33M40.1M53.57M
Depreciation & Amortization1.88M1.6M929K936K569.8K
EBITDA(28.65M)(26.6M)(27M)(32.13M)(41.41M)
EBITDA Margin-416.8%-398.2%-375.0%-300.8%-252.8%
Operating Income(30.29M)(29.6M)(28.62M)(33.06M)(41.98M)
Operating Margin-440.7%-443.1%-397.5%-309.6%-256.3%
Interest Income205K1.06M1.64M1.44M1.09M
Interest Expense67K168.82K770K00
Other Income / Expenses(303K)1.22M200K5.24M(1.08M)
Income Before Tax(30.59M)(28.38M)(28.7M)(27.82M)(43.06M)
Pre-Tax Margin-445.1%-424.8%-398.6%-260.5%-262.9%
Income Tax Expense105K287K(128K)(2K)256.41K
Net Income(30.7M)(28.67M)(28.57M)(27.82M)(43.32M)
Net Margin-446.7%-429.1%-396.8%-260.4%-264.4%
EPS (Basic)(1.50)(1.38)(1.35)(1.12)(1.43)
EPS (Diluted)(1.50)(1.38)(1.35)(1.12)(1.43)
Weighted Avg Shares20.46M20.77M21.18M24.77M30.23M
Weighted Avg Shares (Diluted)20.47M20.77M21.18M24.77M30.23M

Profound Medical Corp.

TSX:PRN.TO

Intrinsic Alpha fair value

Locked

Current Price

$9.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.